Statistical Sampling: an Underestimated Element of Process Validation?
In a recent FDA Warning Letter, the FDA criticized inadequate process validation for a semi-solid dosage form. What exactly did the FDA find inadequate?
The validation studies were criticized for not reflecting inter- and intra-batch variability. In particular, there was criticism that the sampling was random. The viscosity sampling scheme does not lead to statistical confidence in process performance.
In a second Process Performance Qualification (PPQ) study, the influence of a critical excipient on viscosity was to be shown. Again, the FDA criticized that no inter-batch variability was demonstrated. This is not surprising, since only one run was performed.
As measures, the FDA requires:
- a validation programme, starting with product development, the validation itself and the control/monitoring of the processes with regard to intra- and inter-batch variability
- an equipment and premises qualification programme
- a programme for Process Performance Qualification and Continued Process Verification measures.
You can find the entire Warning Letter on the FDA website.
Related GMP News
07.05.2025Media Fill and Smoke Studies: FDA's Perspective
30.04.2025FDA expectations for Media Fills
30.04.2025Qualification of old installations in 2025
26.03.2025Correlation between Validation Master Plan and Validation Protocols
20.03.2025New FDA-Guidance for Industry draft on AI
19.03.2025FDA takes a Look at Cleaning Validation